Redmile Group, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Redmile Group, LLC reported 48 stock positions worth $939.6 million. Its top holding was Scholar Rock (SRRK) at 14.8% of the portfolio, followed by Krystal Biotech (KRYS, 9.7%) and Zymeworks (ZYME, 5.5%). Compared with Q1 2025, it opened 2 new positions, sold out of 10 and reduced 31. The biggest buy was a new position in Hinge Health Class A (HNGE) and the biggest sale Amicus Therapeutics (FOLD, shares −88%).
- Most Recent 13F
- Q2 2026
- Location
- LARKSPUR, CA
- CIK
- 0001425738
- Portfolio Value
- $939.6M (Q2 2025)
- SEC Filing
- 0001104659-25-078608 ↗ filed Aug 14, 2025
Holdings Value
Holdings 48 stocks · $939.6M
| SRRK Scholar Rock Holding Corp. | 14.81% | 3,929,039 | $139.2M | Reduce -10.7% |
| KRYS Krystal Biotech Inc. | 9.71% | 663,471 | $91.2M | Reduce -10.1% |
| ZYME Zymeworks Inc. | 5.54% | 4,150,627 | $52.1M | Reduce -13.3% |
| STOK Stoke Therapeutics Inc. | 5.29% | 4,375,931 | $49.7M | Reduce -2.5% |
| IMNM Immunome Inc. | 4.82% | 4,872,225 | $45.3M | Reduce -9.1% |
| REPL Replimune Group Inc. | 4.61% | 4,664,791 | $43.3M | Reduce -4.8% |
| NRIX Nurix Therapeutics Inc. | 4.53% | 3,732,888 | $42.5M | Reduce -7.9% |
| LIVN Livanova PLC | 4.48% | 934,271 | $42.1M | Reduce -7.9% |
| ADCT Adc Therapeutics SA | 4.47% | 15,666,731 | $42.0M | No change |
| AKRO Akero Therapeutics Inc. | 4.40% | 774,311 | $41.3M | Reduce -17.6% |
| RGNX Regenxbio Inc. | 4.17% | 4,775,717 | $39.2M | Reduce -0.4% |
| KYMR Kymera Therapeutics Inc. | 3.73% | 803,289 | $35.1M | Reduce -18.3% |
| BEAM Beam Therapeutics Inc. | 2.58% | 1,423,411 | $24.2M | Reduce -11.6% |
| ABSI Absci Corp. | 2.26% | 8,253,316 | $21.2M | No change |
| NGNE Neurogene Inc. | 2.03% | 1,276,676 | $19.1M | Reduce -2.4% |
| HNGE Hinge Health Inc. Class A | 1.65% | 300,000 | $15.5M | New |
| ETNB 89BIO Inc. | 1.61% | 1,545,208 | $15.2M | Reduce -18.1% |
| ANNX Annexon Inc. | 1.61% | 6,300,644 | $15.1M | No change |
| FATE Fate Therapeutics Inc. | 1.53% | 12,872,946 | $14.4M | No change |
| SLN Silence Therapeutics PLC-ADR | 1.34% | 2,164,777 | $12.6M | Reduce -2.3% |
| COGT Cogent Biosciences Inc. | 1.11% | 1,448,040 | $10.4M | Reduce -55.0% |
| BHVN Biohaven Ltd. | 1.10% | 729,515 | $10.3M | Reduce -15.9% |
| SLDB Solid Biosciences Inc. | 0.99% | 1,915,926 | $9.3M | Reduce -5.1% |
| BSX Boston Scientific Corp. | 0.98% | 85,301 | $9.2M | Reduce -55.9% |
| IDYA Ideaya Biosciences Inc. | 0.97% | 432,494 | $9.1M | Reduce -19.1% |
| VERV Verve Therapeutics Inc. | 0.88% | 740,261 | $8.3M | Reduce -38.7% |
| CBLL Ceribell Inc. | 0.87% | 435,239 | $8.2M | No change |
| KROS Keros Therapeutics Inc. | 0.79% | 552,506 | $7.4M | No change |
| CLDX Celldex Therapeutics Inc. | 0.74% | 343,026 | $7.0M | Reduce -41.9% |
| FOLD Amicus Therapeutics Inc. | 0.73% | 1,188,998 | $6.8M | Reduce -87.5% |
| NUVB Nuvation Bio Inc. | 0.63% | 3,031,009 | $5.9M | No change |
| ESTA Establishment Labs Holdings | 0.62% | 136,495 | $5.8M | Reduce -59.3% |
| PRME Prime Medicine Inc. | 0.55% | 2,074,350 | $5.1M | No change |
| RAPT Rapt Therapeutics Inc. | 0.54% | 630,686 | $5.0M | New |
| PEN Penumbra Inc. | 0.51% | 18,818 | $4.8M | Reduce -17.6% |
| STTK Shattuck Labs Inc. | 0.47% | 5,539,724 | $4.4M | No change |
| ATRA Atara Biotherapeutics Inc. | 0.36% | 441,701 | $3.4M | No change |
| IGMS Igm Biosciences Inc. | 0.35% | 2,952,131 | $3.3M | No change |
| LVTX Lava Therapeutics NV | 0.29% | 2,074,372 | $2.7M | No change |
| VTYX Ventyx Biosciences Inc. | 0.25% | 1,114,529 | $2.4M | Reduce -29.0% |
| RPTX Repare Therapeutics Inc. | 0.23% | 1,586,174 | $2.2M | Reduce -15.8% |
| XERS Xeris Biopharma Holdings Inc. | 0.22% | 451,099 | $2.1M | No change |
| PLRX Pliant Therapeutics Inc. | 0.20% | 1,632,577 | $1.9M | Reduce -20.5% |
| IVVD Invivyd Inc. | 0.17% | 2,285,320 | $1.6M | No change |
| ALXO Alx Oncology Holdings Inc. | 0.15% | 3,391,455 | $1.4M | Reduce -6.8% |
| BOLD Boundless Bio Inc. | 0.06% | 589,034 | $595K | Reduce -18.8% |
| FDMT 4D Molecular Therapeutics Inc. | 0.04% | 112,168 | $416K | Reduce -88.8% |
| KLRS Kalaris Therapeutics Inc. | 0.02% | 82,955 | $221K | No change |
Portfolio Sells Q1 2025 → Q2 2025
| FOLD Amicus Therapeutics Inc. | Reduce -87.5% | 0.73% | −6.63 |
| KRYS Krystal Biotech Inc. | Reduce -10.1% | 9.71% | −2.86 |
| BHVN Biohaven Ltd. | Reduce -15.9% | 1.10% | −0.88 |
| BSX Boston Scientific Corp. | Reduce -55.9% | 0.98% | −0.87 |
| IMVT Immunovant Inc. | Sold out | 0.00% | −0.79 |
| RAPT THERAPEUTICS INC | Sold out | 0.00% | −0.75 |
| COGT Cogent Biosciences Inc. | Reduce -55.0% | 1.11% | −0.71 |
| ESTA Establishment Labs Holdings | Reduce -59.3% | 0.62% | −0.67 |
| PODD Insulet Corp. | Sold out | 0.00% | −0.67 |
| BNTX Biontech SE-ADR | Sold out | 0.00% | −0.63 |
| IRTC Irhythm Holdings Inc. | Sold out | 0.00% | −0.56 |
| MASI Masimo Corp. | Sold out | 0.00% | −0.41 |
| BEAM Beam Therapeutics Inc. | Reduce -11.6% | 2.58% | −0.40 |
| ORKA Oruka Therapeutics Inc. | Sold out | 0.00% | −0.38 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −0.31 |
| CLDX Celldex Therapeutics Inc. | Reduce -41.9% | 0.74% | −0.27 |
| FDMT 4D Molecular Therapeutics Inc. | Reduce -88.8% | 0.04% | −0.26 |
| ATXS Astria Therapeutics Inc. | Sold out | 0.00% | −0.14 |
| ALXO Alx Oncology Holdings Inc. | Reduce -6.8% | 0.15% | −0.06 |
| PEN Penumbra Inc. | Reduce -17.6% | 0.51% | −0.06 |
| PLRX Pliant Therapeutics Inc. | Reduce -20.5% | 0.20% | −0.06 |
| BOLD Boundless Bio Inc. | Reduce -18.8% | 0.06% | −0.04 |
| NRIX Nurix Therapeutics Inc. | Reduce -7.9% | 4.53% | −0.02 |
| ALLK Allakos LLC | Sold out | 0.00% | −0.02 |
| RPTX Repare Therapeutics Inc. | Reduce -15.8% | 0.23% | +0.06 |
| VTYX Ventyx Biosciences Inc. | Reduce -29.0% | 0.25% | +0.08 |
| REPL Replimune Group Inc. | Reduce -4.8% | 4.61% | +0.10 |
| IDYA Ideaya Biosciences Inc. | Reduce -19.1% | 0.97% | +0.14 |
| ZYME Zymeworks Inc. | Reduce -13.3% | 5.54% | +0.15 |
| SLDB Solid Biosciences Inc. | Reduce -5.1% | 0.99% | +0.29 |
| ETNB 89BIO Inc. | Reduce -18.1% | 1.61% | +0.32 |
| VERV Verve Therapeutics Inc. | Reduce -38.7% | 0.88% | +0.36 |
| NGNE Neurogene Inc. | Reduce -2.4% | 2.03% | +0.58 |
| LIVN Livanova PLC | Reduce -7.9% | 4.48% | +0.71 |
| SLN Silence Therapeutics PLC-ADR | Reduce -2.3% | 1.34% | +0.75 |
| AKRO Akero Therapeutics Inc. | Reduce -17.6% | 4.40% | +0.80 |
| RGNX Regenxbio Inc. | Reduce -0.4% | 4.17% | +0.93 |
| KYMR Kymera Therapeutics Inc. | Reduce -18.3% | 3.73% | +1.19 |
| IMNM Immunome Inc. | Reduce -9.1% | 4.82% | +1.41 |
| SRRK Scholar Rock Holding Corp. | Reduce -10.7% | 14.81% | +1.45 |
| STOK Stoke Therapeutics Inc. | Reduce -2.5% | 5.29% | +2.47 |
Portfolio Buys Q1 2025 → Q2 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $1.5B | SRRK, KRYS, STOK, IMNM, NRIX |
| Q1 2026 | 35 | $1.5B | SRRK, KRYS, STOK, IMNM, NRIX |
| Q4 2025 | 34 | $1.4B | SRRK, KRYS, NRIX, STOK, IMNM |
| Q3 2025 | 40 | $1.0B | SRRK, KRYS, STOK, ZYME, ADCT |
| Q2 2025 | 48 | $939.6M | SRRK, KRYS, ZYME, STOK, IMNM |
| Q1 2025 | 56 | $1.1B | SRRK, KRYS, FOLD, ZYME, NRIX |
| Q4 2024 | 62 | $1.4B | SRRK, KRYS, NRIX, ZYME, FOLD |
| Q3 2024 | 63 | $1.7B | KRYS, NRIX, FOLD, IMNM, KYMR |
| Q2 2024 | 63 | $1.7B | KRYS, FOLD, NRIX, STOK, IMNM |
| Q1 2024 | 77 | $2.7B | KRYS, FOLD, IMNM, SRRK, FATE |